Citius Pharmaceuticals Inc. CTXR

Citius Pharmaceuticals Inc. (CTXR) Recent Headlines

Citius Pharmaceuticals to Present at NobleCon15 Investor Conference

CRANFORD, N.J. , Jan. 25, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, ...

Citius Licenses Mino-Wrap From MD Anderson Cancer Center

CRANFORD, N.J., Jan. 8, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported that a definitive license agreement has been reached with MD Anderson Cancer Center ("MDACC") to develop and commercialize a novel approach to reducing post-operative infections associated with surgical implants. There are approximately 100,000 patients in the U.S. undergoing breast reconstruction procedures following mastectomies.

Citius Pharmaceuticals to Present at Biotech Showcase Investor Conference

CRANFORD, N.J. , Jan. 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, ...

Citius Pharmaceuticals Provides Updates on Mino-Lok® and CITI-002

CRANFORD, N.J., Dec. 19, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a status report today on Mino-Lok® and CITI-002. Mr. Myron Holubiak, CEO of Citius, said, "While there are significant challenges involved with studying an adjunctive therapy in patients with underlying serious life-threatening diseases, we are extremely pleased with the progress that has been made in the Phase-3 Mino-Lok® clinical trials.

Citius Pharmaceuticals Presentation Now Available for On-Demand Viewing

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation CRANFORD, N.J. , Dec. 10, 2018 /PRNewswire/ -- Citius Pharmaceuticals ...

Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th

Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Dec. 4, 2018 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...

Citius Pharmaceuticals to Present at the 11th Annual LD Micro Main Event

CRANFORD, N.J. , Nov. 30, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug ...

Citius Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com December 6

Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com CRANFORD, N.J. , Nov. 29, 2018 /PRNewswire/ --  Citius ...

Citius Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference

CRANFORD, N.J. , Oct. 25, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical ...

Citius Reports On Activities During Infectious Disease Week 2018

The Citius Scientific Advisory Board (SAB) meeting was held on October 4 to discuss the progress of the Mino-Lok® pivotal phase 3 trial and the design of the second trial (if needed). A meeting of many of the principal investigators of the Mino-Lok® pivotal phase 3 trial was also held on October 4, 2018.

Citius Pharmaceuticals Inc. (OTCMRKTS: CTXR) Stock Message Board

1. Company Profile  
2. Time & Sales  
3. Recent News  
4. Filings  
5. Financials  
6. Buy Rating